Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
33%
Ph phase_2
2
22%
Ph phase_1
4
44%

Phase Distribution

4

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(3)
Terminated(3)
Other(2)

Detailed Status

Completed3
Withdrawn3
unknown1
Suspended1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 22 (22.2%)
Phase 33 (33.3%)

Trials by Status

completed333%
unknown111%
withdrawn333%
suspended111%
not_yet_recruiting111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain

NCT05695339
not_yet_recruitingphase_1

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

NCT02522611
suspendedphase_2

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

NCT05067257
unknownphase_2

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT04885972
withdrawnphase_3

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

NCT04572776
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05695339Phase 1

Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain

Completed
NCT02522611Phase 1

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

Not Yet Recruiting
NCT05067257Phase 2

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Suspended
NCT04885972Phase 2

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Unknown
NCT04572776Phase 3

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Withdrawn
NCT04044742Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee

Withdrawn
NCT04386980Phase 3

Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed

Withdrawn
NCT03542838Phase 1

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

Completed
NCT03226574Phase 1

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9